These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31200847)

  • 1. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
    Akamatsu S; Kubota M; Uozumi R; Narita S; Takahashi M; Mitsuzuka K; Hatakeyama S; Sakurai T; Kawamura S; Ishidoya S; Hoshi S; Ishida M; Mizuno K; Ogura K; Goto T; Terada N; Kobayashi T; Yamasaki T; Inoue T; Tsuchiya N; Ohyama C; Arai Y; Habuchi T; Morita S; Ogawa O
    Eur Urol Oncol; 2019 May; 2(3):320-328. PubMed ID: 31200847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
    Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
    Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer.
    Buelens S; De Bleser E; Dhondt B; Verla W; Decaestecker K; Ost P; Fonteyne V; De Man K; Standaert C; Rottey S; Lumen N
    World J Urol; 2019 Dec; 37(12):2565-2571. PubMed ID: 30132067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity.
    Fujiwara H; Kubota M; Hidaka Y; Ito K; Kawahara T; Kurahashi R; Hattori Y; Shiraishi Y; Hama Y; Makita N; Tashiro Y; Hatano S; Ikeuchi R; Nakashima M; Utsunomiya N; Takashima Y; Somiya S; Nagahama K; Fujimoto T; Shimizu K; Imai K; Takahashi T; Sumiyoshi T; Goto T; Morita S; Kobayashi T; Akamatsu S
    Int J Clin Oncol; 2024 Oct; 29(10):1574-1585. PubMed ID: 39028395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
    Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
    PeerJ; 2023; 11():e14500. PubMed ID: 36624752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
    Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
    Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
    Wu T; Zhao J; Liu Z; Shen P; Zhang M; Sun G; Liu J; Liao B; Chen J; Zhu S; Dai J; Wang Z; Zhang H; Zhao P; Zhang X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Oct; 79(14):1673-1682. PubMed ID: 31433509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.
    Yang YJ; Lin GW; Li GX; Dai B; Ye DW; Wu JL; Xie HY; Zhu Y
    Asian J Androl; 2018; 20(2):184-188. PubMed ID: 29111539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
    Narita S; Yanagisawa T; Hatakeyama S; Hata K; Fujita K; Ueda T; Tanaka T; Maita S; Chiba S; Sato H; Sekine Y; Kobayashi M; Kashima S; Yamamoto R; Numakura K; Saito M; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Iwabuchi I; Suzuki T; Ukimura O; Kimura T; Ohyama C; Nomura K; Habuchi T
    Prostate; 2024 Sep; ():. PubMed ID: 39344365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.
    Zhao J; Sun G; Liao B; Zhang X; Armstrong CM; Yin X; Liu J; Chen J; Yang Y; Zhao P; Tang Q; Wang Z; Chen Z; Li X; Wei Q; Li X; Chen N; Gao AC; Shen P; Zeng H
    BJU Int; 2018 Dec; 122(6):994-1002. PubMed ID: 29772102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
    Ikeda T; Ishihara H; Iizuka J; Hashimoto Y; Yoshida K; Kakuta Y; Takagi T; Okumi M; Ishida H; Kondo T; Tanabe K
    Jpn J Clin Oncol; 2020 Aug; 50(8):933-939. PubMed ID: 32303747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
    Buelens S; Poelaert F; Dhondt B; Fonteyne V; De Visschere P; Ost P; Verbeke S; Villeirs G; De Man K; Rottey S; Decaestecker K; Lumen N
    Urol Oncol; 2018 Apr; 36(4):158.e13-158.e20. PubMed ID: 29336978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.
    Joniau S; Briganti A; Gontero P; Gandaglia G; Tosco L; Fieuws S; Tombal B; Marchioro G; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; Van Poppel H; Spahn M;
    Eur Urol; 2015 Jan; 67(1):157-164. PubMed ID: 24486307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.